Viewing nowDapaon Tablet 5mg (Dapagliflozin bis L-Proline)
Dapagliflozin Bis L-proline 7.8mg
Tablet · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

MFDS item code 202003734 · Approved 2020.05.22 · Insurance code 643508260
Improvement of glycemic control in type 2 diabetes; prevention of worsening chronic heart failure and chronic kidney disease
This medication helps improve blood sugar control in patients with type 2 diabetes and can be used alone or in combination with other medications. It also plays a role in reducing the risk of death from cardiovascular disease and hospitalizations due to heart failure in patients with chronic heart failure. In patients with chronic kidney disease, it helps delay the decline in glomerular filtration rate and reduces the risk of death from end-stage kidney disease and cardiovascular disease. This drug is effective in treating diabetes, heart failure, and kidney disease and is used in combination with standard treatments for each condition.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received drug treatment for diabetes, when administered in combination with metformin, the recommended initial dose of this medicine is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR below 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR below 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. There are no relevant data.
This drug should not be administered to certain patients. For example, it should not be given to patients with allergies to the active ingredient or excipients, patients with type 1 diabetes, patients with diabetic ketoacidosis, and patients with certain genetic lactose intolerance issues. Additionally, it should not be taken by patients undergoing dialysis. This drug should be used cautiously in patients with decreased fluid volume or impaired kidney function. It can lower blood pressure or reduce intravascular volume, which may lead to symptomatic hypotension or acute kidney injury. Special care should be taken in patients with reduced kidney function, elderly patients, and those taking diuretics to carefully evaluate fluid status and kidney function before administration, as well as monitor for signs of hypotension and changes in kidney function during administration. Adverse effects such as genital infections, urinary tract infections, hypoglycemia, decreased fluid volume, and diabetic ketoacidosis may occur. Women and patients with a history of infections may be at higher risk for genital infections. Diabetic ketoacidosis can occur even without high blood sugar, so if symptoms like nausea, vomiting, abdominal pain, or difficulty breathing arise, immediate medical attention is necessary. Monitoring blood ketone levels during medication use is recommended. Furthermore, this medication may have a weight loss effect, increasing the risk of decreased fluid volume and hypotension in elderly patients or those with impaired kidney function, requiring special care. Pregnant or breastfeeding women are advised not to use this drug, and if pregnancy is confirmed, administration should be discontinued. When taken in conjunction with insulin or sulfonylureas, the risk of hypoglycemia may increase, necessitating potential dose adjustments for these medications. Finally, while this drug does not significantly affect driving or operating machinery, caution is advised due to the potential for hypoglycemic symptoms.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius.
Yellow, bilaterally convex, round film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowDapagliflozin Bis L-proline 7.8mg
Tablet · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

Dapagliflozin Bis L-proline 15.6mg
Tablet · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

Dapagliflozin Bis L-proline 15.63mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Dapagliflozin Bis L-proline 15.63mg
Tablet · Prescription medication
Boryung Pharm. Co., Ltd.
Dapagliflozin Bis L-proline 15.63mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Dapagliflozin Bis L-proline 15.63mg
Tablet · Prescription medication
Kyungdong Pharmaceutical Co., Ltd.

Dapagliflozin Bis L-proline 7.815mg
Tablet · Prescription medication
Kyungdong Pharmaceutical Co., Ltd.

Dapagliflozin Bis L-proline 7.815mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.